TGRX-678 Chinese Phase II in Chronic Myelogenous Leukemia (CML) Patients

Clinical trial NCT06453902 · RECRUITING

Trial details

NCT number: NCT06453902
Sponsor: Shenzhen TargetRx Co., Ltd.
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Chronic Myeloid Leukemia Accelerated Phase CML

Start date: 2024-07-15
Primary completion: 2026-06-30
Enrollment: 40

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.